Uso de inibidores de SGLT2 como nova terapia medicamentosa no tratamento da doença renal crônica em portadores de diabetes mellitus / Use of SGLT2 inhibitors as a new drug therapy in the treatment of chronic kidney disease in diabetes mellitus patients

Paolla Tomás Vitorino Silva e Silva, Carolina Teixeira Pinto, Fernanda Duarte Oliveira Lage, Gabriela Bianchetti Caetano, João Pedro Donato Veloso, João Vitor Gontijo Araujo, Priscilla Carolina da Silva Cerutti Takahashi Kaneko, Thiago Duarte Pinto Coelho Barcelos, Victoria Moreira Hannas Guimarães

Abstract


O uso de inibidores co-transportador de sódio-glicose-2 (ISGLT2) representa uma nova classe de medicamentos no tratamento da doença renal crônica (DRC), cuja principal causa é o diabetes mellitus do tipo 2 (DM2); devido ao seu efeito glicosúrico, além da atuar nas complicações do DM2, age também nos mecanismos fisiopatológicos da doença. Estudos têm demonstrado que o uso de ISGLT2, a longo prazo, pode auxiliar na preservação da função renal e atrasar o uso de terapia renal substitutiva, pois atuam na redução da albumina filtrada e o trabalho de transporte renal, bem como o consumo de oxigênio; além disso, atuam na redução dos valores de hemoglobina glicada, auxiliando no controle glicêmico do paciente diabético. Outrossim, estudos evidenciam que o uso de ISGLT2 reduz o risco de morte  por eventos cardiovasculares, infarto do miocárdio não fatal ou acidente vascular cerebral não fatal; dessa maneira, o fármaco também apresenta benefícios em pacientes com outras comorbidades, para além da DRC e DM2. Contudo, os mecanismos pelos quais os ISGLT2  atuam ainda não são bem estabelecidos na literatura, principalmente no que diz respeito ao sistema cardiovascular. Nesse sentido, novas pesquisas são necessárias para estabelecer os benefícios e os malefícios do uso dessa medicação a longo prazo.


Keywords


diabetes, doença renal crônica, inibidores de sglt2.

References


BAILEY, C. J.; DAY, C.; BELLARY, S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports, v. 22, n. 1, p. 39–52, jan. 2022.

ČERTÍKOVÁ CHÁBOVÁ, V.; ZAKIYANOV, O. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. International Journal of Molecular Sciences, v. 23, n. 5, p. 2812, 4 mar. 2022.

CHEN, T. K. et al. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA v. 322, n. 13, p. 1294, 1 out. 2019.

GAITONDE, D. Y. et al. Chronic Kidney Disease: Detection and Evaluation. Am Fam Physician, v. 96, n. 12, p. 776, 15 dez. 2017.

GEORGIANOS, P. I. et al. Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease. Journal of Personalized Medicine, v. 12, n. 2, p. 223, 6 fev. 2022.

HEERSPINK, H. J. L. et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, v. 383, n. 15, p. 1436–1446, 8 out. 2020.

HEERSPINK, H. J. L. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, v. 35, n. 2, p. 274–282, 1 fev. 2020.

HU, S. et al. The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, v. 12, 27 jan. 2022.

KALANTAR-ZADEH, K. et al. Chronic kidney disease. Lancet, vol. 398, p. 786-802, 28 ago. 2021.

KELLY, M. S. et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgraduate Medicine, v. 131, n. 1, p. 31–42, 30 nov. 2018.

LI, J. et al. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology, v. 15, n. 11, p. 1678–1688, 9 jun. 2020.

LIOUDAKI, E. et al. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Reviews in Cardiovascular Medicine, v. 23, n. 3, p. 082, 3 mar. 2022.

MCGUIRE, D. K. et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, v. 6, n. 2, p. 148, 1 fev. 2021.

NESPOUX, J.; VALLON, V. SGLT2 inhibition and kidney protection. Clinical Science, v. 132, n. 12, p. 1329–1339, 28 jun. 2018.

NEVOLA, R. et al. Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Reviews in Cardiovascular Medicine, v. 23, n. 3, p. 0106, 17 mar. 2022.

TOYAMA, T. et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, v. 21, n. 5, p. 1237–1250, 4 mar. 2019.

VALLIANOU, N. G. et al. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Current Cardiology Reviews, v. 15, n. 1, p. 55–63, 11 dez. 2018.

VALLON, V.; VERMA, S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annual Review of Physiology, v. 83, n. 1, p. 503–528, 10 fev. 2021.

VASQUEZ-RIOS, G.; NADKARNI, G. N. SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients. International Journal of Nephrology and Renovascular Disease, v. Volume 13, p. 281–296, out. 2020.

WHEELER, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, v. 35, n. 10, p. 1700–1711, 30 ago. 2020.

WINIARSKA, A. et al. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. International Journal of Molecular Sciences, v. 22, n. 19, p. 10822, 6 out. 2021.

YAN, M.T.; CHAO, C.T.; LIN, S.H. Chronic Kidney Disease: Strategies to Retard Progression. Int J Mol Sci, vol. 22, p. 10084, 18 set. 2021.

ZHUANG, Y. et al. Diagnosis of Chronic Kidney Disease by Three-Dimensional Contrast-Enhanced Ultrasound Combined with Augmented Reality Medical Technology. J Healthc Eng,16 mar. 2021.




DOI: https://doi.org/10.34117/bjdv8n5-112